Details for Patent: 8,758,813

Title:	Abuse-deterrent drug formulations
Abstract:	An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
Inventor(s):	Hirsh; Jane (Wellesley, MA), Fleming; Alison (Mansfield, MA), Rariy; Roman (Philadelphia, PA), Klibanov; Alexander M. (Boston, MA)
Assignee:	Collegium Pharmaceutical, Inc. (Canton, MA)
Filing Date:	Apr 25, 2013
Application Number:	13/870,690
Claims:	1. A method for the management of pain comprising administering to a patient in need thereof a therapeutically effective pharmaceutical composition comprising solid microparticles, wherein the microparticles comprise: a) an active agent, b) one or more fatty acids, and c) one or more carrier materials selected from the group consisting of waxes or wax-like substances and mixtures thereof; wherein the active agent comprises a fatty acid salt of oxycodone, and the one or more fatty acids are present in an amount ranging from 6.9 to 15 times the molar amount of the active agent. 2. The method of claim 1, wherein the molar concentration of the one or more fatty acids in the microparticle is 6.9 to 10 times the molar amount of the active agent. 3. The method of claim 1, wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids, one or more C.sub.8 to C.sub.40 divalent fatty acids, or mixtures thereof. 4. The method of claim 2 wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids, one or more C.sub.8 to C.sub.40 divalent fatty acids, or mixtures thereof. 5. The method of claim 3, wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids selected from the group consisting of pentanoic acid, hexanoic (caproic) acid, heptanoic acid, octanoic (carylic) acid, nonanoic acid, decanoic (capric) acid, undecanoic acid, dodecanoic (lauric) acid, tridecanoic acid, tetradecanoic (myristic) acid, pentadecanoic acid, hexadecanoic (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, nonadecanoic acid, eicosanoic (arachidic) acid, heneicosanoic acid, docasanoic (behenic) acid, tricosanoic acid, tetracosanoic (lignoceric) acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, linoleic acid, oleic acid, and mixtures thereof. 6. The method of claim 4, wherein the one or more fatty acids is one or more C.sub.5 to C.sub.30 monovalent fatty acids selected from the group consisting of pentanoic acid, hexanoic (caproic) acid, heptanoic acid, octanoic (carylic) acid, nonanoic acid, decanoic (capric) acid, undecanoic acid, dodecanoic (lauric) acid, tridecanoic acid, tetradecanoic (myristic) acid, pentadecanoic acid, hexadecanoic (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, nonadecanoic acid, eicosanoic (arachidic) acid, heneicosanoic acid, docasanoic (behenic) acid, tricosanoic acid, tetracosanoic (lignoceric) acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, linoleic acid, oleic acid, and mixtures thereof. 7. The method of claim 5, wherein the one or more fatty acids is myristic acid. 8. The method of claim 6, wherein the one or more fatty acids is myristic acid. 9. The method of claim 1, wherein the one or more carrier materials are present in an amount of from 0.25 to 8 times the weight of the amount of active agent. 10. The method of claim 2, wherein the one or more carrier materials are present in an amount of from 0.25 to 8 times the weight of the amount of active agent. 11. The method of claim 9, wherein the one or more carrier materials are present in an amount of from 2 to 6 times by weight of the amount of active agent. 12. The method of claim 10, wherein the one or more carrier materials are present in an amount of from 2 to 6 times by weight of the amount of active agent. 13. The method of claim 1, wherein the carrier material is a wax selected from the group consisting of carnauba wax, beeswax, microcrystalline wax, and mixtures thereof. 14. The method of claim 2, wherein the carrier material is a wax selected from the group consisting of carnauba wax, beeswax, microcrystalline wax, and mixtures thereof. 15. The method of claim 13, wherein the carrier material is a mixture of beeswax and carnauba wax. 16. The method of claim 14, wherein the carrier material is a mixture of beeswax and carnauba wax. 17. The method of claim 1, wherein the active agent comprises a myristic acid salt of oxycodone, the one or more fatty acids is myristic acid, and the carrier comprises beeswax and carnauba wax. 18. The method of claim 2, wherein the active agent comprises a myristic acid salt of oxycodone, the one or more fatty acids is myristic acid, and the carrier comprises beeswax and carnauba wax. 19. The method of claim 1, wherein the active agent is prepared by contacting a molar excess of one of the one or more fatty acids with the free base form of the active agent. 20. The method of claim 2, wherein the active agent is prepared by contacting a molar excess of one of the one or more fatty acids with the free base form of the active agent.